Global Neuroblastoma Treatment Drugs Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
LPI (LP Information)' newest research report, the “Neuroblastoma Treatment Drugs Industry Forecast” looks at past sales and reviews total world Neuroblastoma Treatment Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Neuroblastoma Treatment Drugs sales for 2023 through 2029. With Neuroblastoma Treatment Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neuroblastoma Treatment Drugs industry.
This Insight Report provides a comprehensive analysis of the global Neuroblastoma Treatment Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neuroblastoma Treatment Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Neuroblastoma Treatment Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neuroblastoma Treatment Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neuroblastoma Treatment Drugs.
The global Neuroblastoma Treatment Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Neuroblastoma Treatment Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Neuroblastoma Treatment Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Neuroblastoma Treatment Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Neuroblastoma Treatment Drugs players cover United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Neuroblastoma Treatment Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Neuroblastoma Treatment Drugs market?
What factors are driving Neuroblastoma Treatment Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Neuroblastoma Treatment Drugs market opportunities vary by end market size?
How does Neuroblastoma Treatment Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
LPI (LP Information)' newest research report, the “Neuroblastoma Treatment Drugs Industry Forecast” looks at past sales and reviews total world Neuroblastoma Treatment Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Neuroblastoma Treatment Drugs sales for 2023 through 2029. With Neuroblastoma Treatment Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neuroblastoma Treatment Drugs industry.
This Insight Report provides a comprehensive analysis of the global Neuroblastoma Treatment Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neuroblastoma Treatment Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Neuroblastoma Treatment Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neuroblastoma Treatment Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neuroblastoma Treatment Drugs.
The global Neuroblastoma Treatment Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Neuroblastoma Treatment Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Neuroblastoma Treatment Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Neuroblastoma Treatment Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Neuroblastoma Treatment Drugs players cover United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Neuroblastoma Treatment Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Cyclophosphamide
- Dinutuximab
- Naxitamab
- Doxorubicin Hydrochloride
- Vincristine Sulfate
- Other
- Hospital
- Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- United Therapeutics
- Y-mAbs Therapeutics
- EUSA Pharma
- ANI Pharmaceuticals
- Baxter Healthcare
- Ingenus Pharmaceuticals
- Pfizer
- Hikma Pharmaceuticals
- Teva Pharmaceuticals
What is the 10-year outlook for the global Neuroblastoma Treatment Drugs market?
What factors are driving Neuroblastoma Treatment Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Neuroblastoma Treatment Drugs market opportunities vary by end market size?
How does Neuroblastoma Treatment Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neuroblastoma Treatment Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Neuroblastoma Treatment Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Neuroblastoma Treatment Drugs by Country/Region, 2018, 2022 & 2029
2.2 Neuroblastoma Treatment Drugs Segment by Type
2.2.1 Cyclophosphamide
2.2.2 Dinutuximab
2.2.3 Naxitamab
2.2.4 Doxorubicin Hydrochloride
2.2.5 Vincristine Sulfate
2.2.6 Other
2.3 Neuroblastoma Treatment Drugs Sales by Type
2.3.1 Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Neuroblastoma Treatment Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Neuroblastoma Treatment Drugs Sale Price by Type (2018-2023)
2.4 Neuroblastoma Treatment Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Neuroblastoma Treatment Drugs Sales by Application
2.5.1 Global Neuroblastoma Treatment Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Neuroblastoma Treatment Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Neuroblastoma Treatment Drugs Sale Price by Application (2018-2023)
3 GLOBAL NEUROBLASTOMA TREATMENT DRUGS BY COMPANY
3.1 Global Neuroblastoma Treatment Drugs Breakdown Data by Company
3.1.1 Global Neuroblastoma Treatment Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Neuroblastoma Treatment Drugs Sales Market Share by Company (2018-2023)
3.2 Global Neuroblastoma Treatment Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Neuroblastoma Treatment Drugs Revenue by Company (2018-2023)
3.2.2 Global Neuroblastoma Treatment Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Neuroblastoma Treatment Drugs Sale Price by Company
3.4 Key Manufacturers Neuroblastoma Treatment Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neuroblastoma Treatment Drugs Product Location Distribution
3.4.2 Players Neuroblastoma Treatment Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NEUROBLASTOMA TREATMENT DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Neuroblastoma Treatment Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Neuroblastoma Treatment Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Neuroblastoma Treatment Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Neuroblastoma Treatment Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Neuroblastoma Treatment Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Neuroblastoma Treatment Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Neuroblastoma Treatment Drugs Sales Growth
4.4 APAC Neuroblastoma Treatment Drugs Sales Growth
4.5 Europe Neuroblastoma Treatment Drugs Sales Growth
4.6 Middle East & Africa Neuroblastoma Treatment Drugs Sales Growth
5 AMERICAS
5.1 Americas Neuroblastoma Treatment Drugs Sales by Country
5.1.1 Americas Neuroblastoma Treatment Drugs Sales by Country (2018-2023)
5.1.2 Americas Neuroblastoma Treatment Drugs Revenue by Country (2018-2023)
5.2 Americas Neuroblastoma Treatment Drugs Sales by Type
5.3 Americas Neuroblastoma Treatment Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neuroblastoma Treatment Drugs Sales by Region
6.1.1 APAC Neuroblastoma Treatment Drugs Sales by Region (2018-2023)
6.1.2 APAC Neuroblastoma Treatment Drugs Revenue by Region (2018-2023)
6.2 APAC Neuroblastoma Treatment Drugs Sales by Type
6.3 APAC Neuroblastoma Treatment Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Neuroblastoma Treatment Drugs by Country
7.1.1 Europe Neuroblastoma Treatment Drugs Sales by Country (2018-2023)
7.1.2 Europe Neuroblastoma Treatment Drugs Revenue by Country (2018-2023)
7.2 Europe Neuroblastoma Treatment Drugs Sales by Type
7.3 Europe Neuroblastoma Treatment Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neuroblastoma Treatment Drugs by Country
8.1.1 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Neuroblastoma Treatment Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Type
8.3 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neuroblastoma Treatment Drugs
10.3 Manufacturing Process Analysis of Neuroblastoma Treatment Drugs
10.4 Industry Chain Structure of Neuroblastoma Treatment Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neuroblastoma Treatment Drugs Distributors
11.3 Neuroblastoma Treatment Drugs Customer
12 WORLD FORECAST REVIEW FOR NEUROBLASTOMA TREATMENT DRUGS BY GEOGRAPHIC REGION
12.1 Global Neuroblastoma Treatment Drugs Market Size Forecast by Region
12.1.1 Global Neuroblastoma Treatment Drugs Forecast by Region (2024-2029)
12.1.2 Global Neuroblastoma Treatment Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Neuroblastoma Treatment Drugs Forecast by Type
12.7 Global Neuroblastoma Treatment Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 United Therapeutics
13.1.1 United Therapeutics Company Information
13.1.2 United Therapeutics Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.1.3 United Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 United Therapeutics Main Business Overview
13.1.5 United Therapeutics Latest Developments
13.2 Y-mAbs Therapeutics
13.2.1 Y-mAbs Therapeutics Company Information
13.2.2 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.2.3 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Y-mAbs Therapeutics Main Business Overview
13.2.5 Y-mAbs Therapeutics Latest Developments
13.3 EUSA Pharma
13.3.1 EUSA Pharma Company Information
13.3.2 EUSA Pharma Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.3.3 EUSA Pharma Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 EUSA Pharma Main Business Overview
13.3.5 EUSA Pharma Latest Developments
13.4 ANI Pharmaceuticals
13.4.1 ANI Pharmaceuticals Company Information
13.4.2 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.4.3 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 ANI Pharmaceuticals Main Business Overview
13.4.5 ANI Pharmaceuticals Latest Developments
13.5 Baxter Healthcare
13.5.1 Baxter Healthcare Company Information
13.5.2 Baxter Healthcare Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.5.3 Baxter Healthcare Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Baxter Healthcare Main Business Overview
13.5.5 Baxter Healthcare Latest Developments
13.6 Ingenus Pharmaceuticals
13.6.1 Ingenus Pharmaceuticals Company Information
13.6.2 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.6.3 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Ingenus Pharmaceuticals Main Business Overview
13.6.5 Ingenus Pharmaceuticals Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.7.3 Pfizer Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 Hikma Pharmaceuticals
13.8.1 Hikma Pharmaceuticals Company Information
13.8.2 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.8.3 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Hikma Pharmaceuticals Main Business Overview
13.8.5 Hikma Pharmaceuticals Latest Developments
13.9 Teva Pharmaceuticals
13.9.1 Teva Pharmaceuticals Company Information
13.9.2 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.9.3 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Teva Pharmaceuticals Main Business Overview
13.9.5 Teva Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neuroblastoma Treatment Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Neuroblastoma Treatment Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Neuroblastoma Treatment Drugs by Country/Region, 2018, 2022 & 2029
2.2 Neuroblastoma Treatment Drugs Segment by Type
2.2.1 Cyclophosphamide
2.2.2 Dinutuximab
2.2.3 Naxitamab
2.2.4 Doxorubicin Hydrochloride
2.2.5 Vincristine Sulfate
2.2.6 Other
2.3 Neuroblastoma Treatment Drugs Sales by Type
2.3.1 Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Neuroblastoma Treatment Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Neuroblastoma Treatment Drugs Sale Price by Type (2018-2023)
2.4 Neuroblastoma Treatment Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Neuroblastoma Treatment Drugs Sales by Application
2.5.1 Global Neuroblastoma Treatment Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Neuroblastoma Treatment Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Neuroblastoma Treatment Drugs Sale Price by Application (2018-2023)
3 GLOBAL NEUROBLASTOMA TREATMENT DRUGS BY COMPANY
3.1 Global Neuroblastoma Treatment Drugs Breakdown Data by Company
3.1.1 Global Neuroblastoma Treatment Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Neuroblastoma Treatment Drugs Sales Market Share by Company (2018-2023)
3.2 Global Neuroblastoma Treatment Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Neuroblastoma Treatment Drugs Revenue by Company (2018-2023)
3.2.2 Global Neuroblastoma Treatment Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Neuroblastoma Treatment Drugs Sale Price by Company
3.4 Key Manufacturers Neuroblastoma Treatment Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neuroblastoma Treatment Drugs Product Location Distribution
3.4.2 Players Neuroblastoma Treatment Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NEUROBLASTOMA TREATMENT DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Neuroblastoma Treatment Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Neuroblastoma Treatment Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Neuroblastoma Treatment Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Neuroblastoma Treatment Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Neuroblastoma Treatment Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Neuroblastoma Treatment Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Neuroblastoma Treatment Drugs Sales Growth
4.4 APAC Neuroblastoma Treatment Drugs Sales Growth
4.5 Europe Neuroblastoma Treatment Drugs Sales Growth
4.6 Middle East & Africa Neuroblastoma Treatment Drugs Sales Growth
5 AMERICAS
5.1 Americas Neuroblastoma Treatment Drugs Sales by Country
5.1.1 Americas Neuroblastoma Treatment Drugs Sales by Country (2018-2023)
5.1.2 Americas Neuroblastoma Treatment Drugs Revenue by Country (2018-2023)
5.2 Americas Neuroblastoma Treatment Drugs Sales by Type
5.3 Americas Neuroblastoma Treatment Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neuroblastoma Treatment Drugs Sales by Region
6.1.1 APAC Neuroblastoma Treatment Drugs Sales by Region (2018-2023)
6.1.2 APAC Neuroblastoma Treatment Drugs Revenue by Region (2018-2023)
6.2 APAC Neuroblastoma Treatment Drugs Sales by Type
6.3 APAC Neuroblastoma Treatment Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Neuroblastoma Treatment Drugs by Country
7.1.1 Europe Neuroblastoma Treatment Drugs Sales by Country (2018-2023)
7.1.2 Europe Neuroblastoma Treatment Drugs Revenue by Country (2018-2023)
7.2 Europe Neuroblastoma Treatment Drugs Sales by Type
7.3 Europe Neuroblastoma Treatment Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neuroblastoma Treatment Drugs by Country
8.1.1 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Neuroblastoma Treatment Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Type
8.3 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neuroblastoma Treatment Drugs
10.3 Manufacturing Process Analysis of Neuroblastoma Treatment Drugs
10.4 Industry Chain Structure of Neuroblastoma Treatment Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neuroblastoma Treatment Drugs Distributors
11.3 Neuroblastoma Treatment Drugs Customer
12 WORLD FORECAST REVIEW FOR NEUROBLASTOMA TREATMENT DRUGS BY GEOGRAPHIC REGION
12.1 Global Neuroblastoma Treatment Drugs Market Size Forecast by Region
12.1.1 Global Neuroblastoma Treatment Drugs Forecast by Region (2024-2029)
12.1.2 Global Neuroblastoma Treatment Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Neuroblastoma Treatment Drugs Forecast by Type
12.7 Global Neuroblastoma Treatment Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 United Therapeutics
13.1.1 United Therapeutics Company Information
13.1.2 United Therapeutics Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.1.3 United Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 United Therapeutics Main Business Overview
13.1.5 United Therapeutics Latest Developments
13.2 Y-mAbs Therapeutics
13.2.1 Y-mAbs Therapeutics Company Information
13.2.2 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.2.3 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Y-mAbs Therapeutics Main Business Overview
13.2.5 Y-mAbs Therapeutics Latest Developments
13.3 EUSA Pharma
13.3.1 EUSA Pharma Company Information
13.3.2 EUSA Pharma Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.3.3 EUSA Pharma Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 EUSA Pharma Main Business Overview
13.3.5 EUSA Pharma Latest Developments
13.4 ANI Pharmaceuticals
13.4.1 ANI Pharmaceuticals Company Information
13.4.2 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.4.3 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 ANI Pharmaceuticals Main Business Overview
13.4.5 ANI Pharmaceuticals Latest Developments
13.5 Baxter Healthcare
13.5.1 Baxter Healthcare Company Information
13.5.2 Baxter Healthcare Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.5.3 Baxter Healthcare Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Baxter Healthcare Main Business Overview
13.5.5 Baxter Healthcare Latest Developments
13.6 Ingenus Pharmaceuticals
13.6.1 Ingenus Pharmaceuticals Company Information
13.6.2 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.6.3 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Ingenus Pharmaceuticals Main Business Overview
13.6.5 Ingenus Pharmaceuticals Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.7.3 Pfizer Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 Hikma Pharmaceuticals
13.8.1 Hikma Pharmaceuticals Company Information
13.8.2 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.8.3 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Hikma Pharmaceuticals Main Business Overview
13.8.5 Hikma Pharmaceuticals Latest Developments
13.9 Teva Pharmaceuticals
13.9.1 Teva Pharmaceuticals Company Information
13.9.2 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
13.9.3 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Teva Pharmaceuticals Main Business Overview
13.9.5 Teva Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Neuroblastoma Treatment Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Neuroblastoma Treatment Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Cyclophosphamide
Table 4. Major Players of Dinutuximab
Table 5. Major Players of Naxitamab
Table 6. Major Players of Doxorubicin Hydrochloride
Table 7. Major Players of Vincristine Sulfate
Table 8. Major Players of Other
Table 9. Global Neuroblastoma Treatment Drugs Sales by Type (2018-2023) & (K Units)
Table 10. Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2018-2023)
Table 11. Global Neuroblastoma Treatment Drugs Revenue by Type (2018-2023) & ($ million)
Table 12. Global Neuroblastoma Treatment Drugs Revenue Market Share by Type (2018-2023)
Table 13. Global Neuroblastoma Treatment Drugs Sale Price by Type (2018-2023) & (US$/Unit)
Table 14. Global Neuroblastoma Treatment Drugs Sales by Application (2018-2023) & (K Units)
Table 15. Global Neuroblastoma Treatment Drugs Sales Market Share by Application (2018-2023)
Table 16. Global Neuroblastoma Treatment Drugs Revenue by Application (2018-2023)
Table 17. Global Neuroblastoma Treatment Drugs Revenue Market Share by Application (2018-2023)
Table 18. Global Neuroblastoma Treatment Drugs Sale Price by Application (2018-2023) & (US$/Unit)
Table 19. Global Neuroblastoma Treatment Drugs Sales by Company (2018-2023) & (K Units)
Table 20. Global Neuroblastoma Treatment Drugs Sales Market Share by Company (2018-2023)
Table 21. Global Neuroblastoma Treatment Drugs Revenue by Company (2018-2023) ($ Millions)
Table 22. Global Neuroblastoma Treatment Drugs Revenue Market Share by Company (2018-2023)
Table 23. Global Neuroblastoma Treatment Drugs Sale Price by Company (2018-2023) & (US$/Unit)
Table 24. Key Manufacturers Neuroblastoma Treatment Drugs Producing Area Distribution and Sales Area
Table 25. Players Neuroblastoma Treatment Drugs Products Offered
Table 26. Neuroblastoma Treatment Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Neuroblastoma Treatment Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 30. Global Neuroblastoma Treatment Drugs Sales Market Share Geographic Region (2018-2023)
Table 31. Global Neuroblastoma Treatment Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 32. Global Neuroblastoma Treatment Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 33. Global Neuroblastoma Treatment Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 34. Global Neuroblastoma Treatment Drugs Sales Market Share by Country/Region (2018-2023)
Table 35. Global Neuroblastoma Treatment Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 36. Global Neuroblastoma Treatment Drugs Revenue Market Share by Country/Region (2018-2023)
Table 37. Americas Neuroblastoma Treatment Drugs Sales by Country (2018-2023) & (K Units)
Table 38. Americas Neuroblastoma Treatment Drugs Sales Market Share by Country (2018-2023)
Table 39. Americas Neuroblastoma Treatment Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 40. Americas Neuroblastoma Treatment Drugs Revenue Market Share by Country (2018-2023)
Table 41. Americas Neuroblastoma Treatment Drugs Sales by Type (2018-2023) & (K Units)
Table 42. Americas Neuroblastoma Treatment Drugs Sales by Application (2018-2023) & (K Units)
Table 43. APAC Neuroblastoma Treatment Drugs Sales by Region (2018-2023) & (K Units)
Table 44. APAC Neuroblastoma Treatment Drugs Sales Market Share by Region (2018-2023)
Table 45. APAC Neuroblastoma Treatment Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 46. APAC Neuroblastoma Treatment Drugs Revenue Market Share by Region (2018-2023)
Table 47. APAC Neuroblastoma Treatment Drugs Sales by Type (2018-2023) & (K Units)
Table 48. APAC Neuroblastoma Treatment Drugs Sales by Application (2018-2023) & (K Units)
Table 49. Europe Neuroblastoma Treatment Drugs Sales by Country (2018-2023) & (K Units)
Table 50. Europe Neuroblastoma Treatment Drugs Sales Market Share by Country (2018-2023)
Table 51. Europe Neuroblastoma Treatment Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 52. Europe Neuroblastoma Treatment Drugs Revenue Market Share by Country (2018-2023)
Table 53. Europe Neuroblastoma Treatment Drugs Sales by Type (2018-2023) & (K Units)
Table 54. Europe Neuroblastoma Treatment Drugs Sales by Application (2018-2023) & (K Units)
Table 55. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Country (2018-2023) & (K Units)
Table 56. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Country (2018-2023)
Table 57. Middle East & Africa Neuroblastoma Treatment Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 58. Middle East & Africa Neuroblastoma Treatment Drugs Revenue Market Share by Country (2018-2023)
Table 59. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Type (2018-2023) & (K Units)
Table 60. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Application (2018-2023) & (K Units)
Table 61. Key Market Drivers & Growth Opportunities of Neuroblastoma Treatment Drugs
Table 62. Key Market Challenges & Risks of Neuroblastoma Treatment Drugs
Table 63. Key Industry Trends of Neuroblastoma Treatment Drugs
Table 64. Neuroblastoma Treatment Drugs Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. Neuroblastoma Treatment Drugs Distributors List
Table 67. Neuroblastoma Treatment Drugs Customer List
Table 68. Global Neuroblastoma Treatment Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 69. Global Neuroblastoma Treatment Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Americas Neuroblastoma Treatment Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Americas Neuroblastoma Treatment Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. APAC Neuroblastoma Treatment Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 73. APAC Neuroblastoma Treatment Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 74. Europe Neuroblastoma Treatment Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Europe Neuroblastoma Treatment Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Middle East & Africa Neuroblastoma Treatment Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 77. Middle East & Africa Neuroblastoma Treatment Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 78. Global Neuroblastoma Treatment Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 79. Global Neuroblastoma Treatment Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 80. Global Neuroblastoma Treatment Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 81. Global Neuroblastoma Treatment Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 82. United Therapeutics Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. United Therapeutics Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 84. United Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 85. United Therapeutics Main Business
Table 86. United Therapeutics Latest Developments
Table 87. Y-mAbs Therapeutics Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 89. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 90. Y-mAbs Therapeutics Main Business
Table 91. Y-mAbs Therapeutics Latest Developments
Table 92. EUSA Pharma Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. EUSA Pharma Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 94. EUSA Pharma Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 95. EUSA Pharma Main Business
Table 96. EUSA Pharma Latest Developments
Table 97. ANI Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 99. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 100. ANI Pharmaceuticals Main Business
Table 101. ANI Pharmaceuticals Latest Developments
Table 102. Baxter Healthcare Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Baxter Healthcare Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 104. Baxter Healthcare Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 105. Baxter Healthcare Main Business
Table 106. Baxter Healthcare Latest Developments
Table 107. Ingenus Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 109. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. Ingenus Pharmaceuticals Main Business
Table 111. Ingenus Pharmaceuticals Latest Developments
Table 112. Pfizer Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. Pfizer Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 114. Pfizer Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. Pfizer Main Business
Table 116. Pfizer Latest Developments
Table 117. Hikma Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 119. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Hikma Pharmaceuticals Main Business
Table 121. Hikma Pharmaceuticals Latest Developments
Table 122. Teva Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 123. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 124. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 125. Teva Pharmaceuticals Main Business
Table 126. Teva Pharmaceuticals Latest Developments
Table 1. Neuroblastoma Treatment Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Neuroblastoma Treatment Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Cyclophosphamide
Table 4. Major Players of Dinutuximab
Table 5. Major Players of Naxitamab
Table 6. Major Players of Doxorubicin Hydrochloride
Table 7. Major Players of Vincristine Sulfate
Table 8. Major Players of Other
Table 9. Global Neuroblastoma Treatment Drugs Sales by Type (2018-2023) & (K Units)
Table 10. Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2018-2023)
Table 11. Global Neuroblastoma Treatment Drugs Revenue by Type (2018-2023) & ($ million)
Table 12. Global Neuroblastoma Treatment Drugs Revenue Market Share by Type (2018-2023)
Table 13. Global Neuroblastoma Treatment Drugs Sale Price by Type (2018-2023) & (US$/Unit)
Table 14. Global Neuroblastoma Treatment Drugs Sales by Application (2018-2023) & (K Units)
Table 15. Global Neuroblastoma Treatment Drugs Sales Market Share by Application (2018-2023)
Table 16. Global Neuroblastoma Treatment Drugs Revenue by Application (2018-2023)
Table 17. Global Neuroblastoma Treatment Drugs Revenue Market Share by Application (2018-2023)
Table 18. Global Neuroblastoma Treatment Drugs Sale Price by Application (2018-2023) & (US$/Unit)
Table 19. Global Neuroblastoma Treatment Drugs Sales by Company (2018-2023) & (K Units)
Table 20. Global Neuroblastoma Treatment Drugs Sales Market Share by Company (2018-2023)
Table 21. Global Neuroblastoma Treatment Drugs Revenue by Company (2018-2023) ($ Millions)
Table 22. Global Neuroblastoma Treatment Drugs Revenue Market Share by Company (2018-2023)
Table 23. Global Neuroblastoma Treatment Drugs Sale Price by Company (2018-2023) & (US$/Unit)
Table 24. Key Manufacturers Neuroblastoma Treatment Drugs Producing Area Distribution and Sales Area
Table 25. Players Neuroblastoma Treatment Drugs Products Offered
Table 26. Neuroblastoma Treatment Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Neuroblastoma Treatment Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 30. Global Neuroblastoma Treatment Drugs Sales Market Share Geographic Region (2018-2023)
Table 31. Global Neuroblastoma Treatment Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 32. Global Neuroblastoma Treatment Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 33. Global Neuroblastoma Treatment Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 34. Global Neuroblastoma Treatment Drugs Sales Market Share by Country/Region (2018-2023)
Table 35. Global Neuroblastoma Treatment Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 36. Global Neuroblastoma Treatment Drugs Revenue Market Share by Country/Region (2018-2023)
Table 37. Americas Neuroblastoma Treatment Drugs Sales by Country (2018-2023) & (K Units)
Table 38. Americas Neuroblastoma Treatment Drugs Sales Market Share by Country (2018-2023)
Table 39. Americas Neuroblastoma Treatment Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 40. Americas Neuroblastoma Treatment Drugs Revenue Market Share by Country (2018-2023)
Table 41. Americas Neuroblastoma Treatment Drugs Sales by Type (2018-2023) & (K Units)
Table 42. Americas Neuroblastoma Treatment Drugs Sales by Application (2018-2023) & (K Units)
Table 43. APAC Neuroblastoma Treatment Drugs Sales by Region (2018-2023) & (K Units)
Table 44. APAC Neuroblastoma Treatment Drugs Sales Market Share by Region (2018-2023)
Table 45. APAC Neuroblastoma Treatment Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 46. APAC Neuroblastoma Treatment Drugs Revenue Market Share by Region (2018-2023)
Table 47. APAC Neuroblastoma Treatment Drugs Sales by Type (2018-2023) & (K Units)
Table 48. APAC Neuroblastoma Treatment Drugs Sales by Application (2018-2023) & (K Units)
Table 49. Europe Neuroblastoma Treatment Drugs Sales by Country (2018-2023) & (K Units)
Table 50. Europe Neuroblastoma Treatment Drugs Sales Market Share by Country (2018-2023)
Table 51. Europe Neuroblastoma Treatment Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 52. Europe Neuroblastoma Treatment Drugs Revenue Market Share by Country (2018-2023)
Table 53. Europe Neuroblastoma Treatment Drugs Sales by Type (2018-2023) & (K Units)
Table 54. Europe Neuroblastoma Treatment Drugs Sales by Application (2018-2023) & (K Units)
Table 55. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Country (2018-2023) & (K Units)
Table 56. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Country (2018-2023)
Table 57. Middle East & Africa Neuroblastoma Treatment Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 58. Middle East & Africa Neuroblastoma Treatment Drugs Revenue Market Share by Country (2018-2023)
Table 59. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Type (2018-2023) & (K Units)
Table 60. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Application (2018-2023) & (K Units)
Table 61. Key Market Drivers & Growth Opportunities of Neuroblastoma Treatment Drugs
Table 62. Key Market Challenges & Risks of Neuroblastoma Treatment Drugs
Table 63. Key Industry Trends of Neuroblastoma Treatment Drugs
Table 64. Neuroblastoma Treatment Drugs Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. Neuroblastoma Treatment Drugs Distributors List
Table 67. Neuroblastoma Treatment Drugs Customer List
Table 68. Global Neuroblastoma Treatment Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 69. Global Neuroblastoma Treatment Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Americas Neuroblastoma Treatment Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Americas Neuroblastoma Treatment Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. APAC Neuroblastoma Treatment Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 73. APAC Neuroblastoma Treatment Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 74. Europe Neuroblastoma Treatment Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Europe Neuroblastoma Treatment Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Middle East & Africa Neuroblastoma Treatment Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 77. Middle East & Africa Neuroblastoma Treatment Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 78. Global Neuroblastoma Treatment Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 79. Global Neuroblastoma Treatment Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 80. Global Neuroblastoma Treatment Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 81. Global Neuroblastoma Treatment Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 82. United Therapeutics Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. United Therapeutics Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 84. United Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 85. United Therapeutics Main Business
Table 86. United Therapeutics Latest Developments
Table 87. Y-mAbs Therapeutics Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 89. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 90. Y-mAbs Therapeutics Main Business
Table 91. Y-mAbs Therapeutics Latest Developments
Table 92. EUSA Pharma Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. EUSA Pharma Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 94. EUSA Pharma Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 95. EUSA Pharma Main Business
Table 96. EUSA Pharma Latest Developments
Table 97. ANI Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 99. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 100. ANI Pharmaceuticals Main Business
Table 101. ANI Pharmaceuticals Latest Developments
Table 102. Baxter Healthcare Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Baxter Healthcare Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 104. Baxter Healthcare Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 105. Baxter Healthcare Main Business
Table 106. Baxter Healthcare Latest Developments
Table 107. Ingenus Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 109. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. Ingenus Pharmaceuticals Main Business
Table 111. Ingenus Pharmaceuticals Latest Developments
Table 112. Pfizer Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. Pfizer Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 114. Pfizer Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. Pfizer Main Business
Table 116. Pfizer Latest Developments
Table 117. Hikma Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 119. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Hikma Pharmaceuticals Main Business
Table 121. Hikma Pharmaceuticals Latest Developments
Table 122. Teva Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
Table 123. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolios and Specifications
Table 124. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 125. Teva Pharmaceuticals Main Business
Table 126. Teva Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Neuroblastoma Treatment Drugs
Figure 2. Neuroblastoma Treatment Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neuroblastoma Treatment Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Neuroblastoma Treatment Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Neuroblastoma Treatment Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Cyclophosphamide
Figure 10. Product Picture of Dinutuximab
Figure 11. Product Picture of Naxitamab
Figure 12. Product Picture of Doxorubicin Hydrochloride
Figure 13. Product Picture of Vincristine Sulfate
Figure 14. Product Picture of Other
Figure 15. Global Neuroblastoma Treatment Drugs Sales Market Share by Type in 2022
Figure 16. Global Neuroblastoma Treatment Drugs Revenue Market Share by Type (2018-2023)
Figure 17. Neuroblastoma Treatment Drugs Consumed in Hospital
Figure 18. Global Neuroblastoma Treatment Drugs Market: Hospital (2018-2023) & (K Units)
Figure 19. Neuroblastoma Treatment Drugs Consumed in Clinic
Figure 20. Global Neuroblastoma Treatment Drugs Market: Clinic (2018-2023) & (K Units)
Figure 21. Neuroblastoma Treatment Drugs Consumed in Other
Figure 22. Global Neuroblastoma Treatment Drugs Market: Other (2018-2023) & (K Units)
Figure 23. Global Neuroblastoma Treatment Drugs Sales Market Share by Application (2022)
Figure 24. Global Neuroblastoma Treatment Drugs Revenue Market Share by Application in 2022
Figure 25. Neuroblastoma Treatment Drugs Sales Market by Company in 2022 (K Units)
Figure 26. Global Neuroblastoma Treatment Drugs Sales Market Share by Company in 2022
Figure 27. Neuroblastoma Treatment Drugs Revenue Market by Company in 2022 ($ Million)
Figure 28. Global Neuroblastoma Treatment Drugs Revenue Market Share by Company in 2022
Figure 29. Global Neuroblastoma Treatment Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 30. Global Neuroblastoma Treatment Drugs Revenue Market Share by Geographic Region in 2022
Figure 31. Americas Neuroblastoma Treatment Drugs Sales 2018-2023 (K Units)
Figure 32. Americas Neuroblastoma Treatment Drugs Revenue 2018-2023 ($ Millions)
Figure 33. APAC Neuroblastoma Treatment Drugs Sales 2018-2023 (K Units)
Figure 34. APAC Neuroblastoma Treatment Drugs Revenue 2018-2023 ($ Millions)
Figure 35. Europe Neuroblastoma Treatment Drugs Sales 2018-2023 (K Units)
Figure 36. Europe Neuroblastoma Treatment Drugs Revenue 2018-2023 ($ Millions)
Figure 37. Middle East & Africa Neuroblastoma Treatment Drugs Sales 2018-2023 (K Units)
Figure 38. Middle East & Africa Neuroblastoma Treatment Drugs Revenue 2018-2023 ($ Millions)
Figure 39. Americas Neuroblastoma Treatment Drugs Sales Market Share by Country in 2022
Figure 40. Americas Neuroblastoma Treatment Drugs Revenue Market Share by Country in 2022
Figure 41. Americas Neuroblastoma Treatment Drugs Sales Market Share by Type (2018-2023)
Figure 42. Americas Neuroblastoma Treatment Drugs Sales Market Share by Application (2018-2023)
Figure 43. United States Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. Canada Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 45. Mexico Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 46. Brazil Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 47. APAC Neuroblastoma Treatment Drugs Sales Market Share by Region in 2022
Figure 48. APAC Neuroblastoma Treatment Drugs Revenue Market Share by Regions in 2022
Figure 49. APAC Neuroblastoma Treatment Drugs Sales Market Share by Type (2018-2023)
Figure 50. APAC Neuroblastoma Treatment Drugs Sales Market Share by Application (2018-2023)
Figure 51. China Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. Japan Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. South Korea Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. Southeast Asia Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. India Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. Australia Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 57. China Taiwan Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 58. Europe Neuroblastoma Treatment Drugs Sales Market Share by Country in 2022
Figure 59. Europe Neuroblastoma Treatment Drugs Revenue Market Share by Country in 2022
Figure 60. Europe Neuroblastoma Treatment Drugs Sales Market Share by Type (2018-2023)
Figure 61. Europe Neuroblastoma Treatment Drugs Sales Market Share by Application (2018-2023)
Figure 62. Germany Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. France Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. UK Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 65. Italy Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 66. Russia Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 67. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Country in 2022
Figure 68. Middle East & Africa Neuroblastoma Treatment Drugs Revenue Market Share by Country in 2022
Figure 69. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Type (2018-2023)
Figure 70. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Application (2018-2023)
Figure 71. Egypt Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. South Africa Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. Israel Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 74. Turkey Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 75. GCC Country Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 76. Manufacturing Cost Structure Analysis of Neuroblastoma Treatment Drugs in 2022
Figure 77. Manufacturing Process Analysis of Neuroblastoma Treatment Drugs
Figure 78. Industry Chain Structure of Neuroblastoma Treatment Drugs
Figure 79. Channels of Distribution
Figure 80. Global Neuroblastoma Treatment Drugs Sales Market Forecast by Region (2024-2029)
Figure 81. Global Neuroblastoma Treatment Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 82. Global Neuroblastoma Treatment Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 83. Global Neuroblastoma Treatment Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 84. Global Neuroblastoma Treatment Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 85. Global Neuroblastoma Treatment Drugs Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Neuroblastoma Treatment Drugs
Figure 2. Neuroblastoma Treatment Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neuroblastoma Treatment Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Neuroblastoma Treatment Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Neuroblastoma Treatment Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Cyclophosphamide
Figure 10. Product Picture of Dinutuximab
Figure 11. Product Picture of Naxitamab
Figure 12. Product Picture of Doxorubicin Hydrochloride
Figure 13. Product Picture of Vincristine Sulfate
Figure 14. Product Picture of Other
Figure 15. Global Neuroblastoma Treatment Drugs Sales Market Share by Type in 2022
Figure 16. Global Neuroblastoma Treatment Drugs Revenue Market Share by Type (2018-2023)
Figure 17. Neuroblastoma Treatment Drugs Consumed in Hospital
Figure 18. Global Neuroblastoma Treatment Drugs Market: Hospital (2018-2023) & (K Units)
Figure 19. Neuroblastoma Treatment Drugs Consumed in Clinic
Figure 20. Global Neuroblastoma Treatment Drugs Market: Clinic (2018-2023) & (K Units)
Figure 21. Neuroblastoma Treatment Drugs Consumed in Other
Figure 22. Global Neuroblastoma Treatment Drugs Market: Other (2018-2023) & (K Units)
Figure 23. Global Neuroblastoma Treatment Drugs Sales Market Share by Application (2022)
Figure 24. Global Neuroblastoma Treatment Drugs Revenue Market Share by Application in 2022
Figure 25. Neuroblastoma Treatment Drugs Sales Market by Company in 2022 (K Units)
Figure 26. Global Neuroblastoma Treatment Drugs Sales Market Share by Company in 2022
Figure 27. Neuroblastoma Treatment Drugs Revenue Market by Company in 2022 ($ Million)
Figure 28. Global Neuroblastoma Treatment Drugs Revenue Market Share by Company in 2022
Figure 29. Global Neuroblastoma Treatment Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 30. Global Neuroblastoma Treatment Drugs Revenue Market Share by Geographic Region in 2022
Figure 31. Americas Neuroblastoma Treatment Drugs Sales 2018-2023 (K Units)
Figure 32. Americas Neuroblastoma Treatment Drugs Revenue 2018-2023 ($ Millions)
Figure 33. APAC Neuroblastoma Treatment Drugs Sales 2018-2023 (K Units)
Figure 34. APAC Neuroblastoma Treatment Drugs Revenue 2018-2023 ($ Millions)
Figure 35. Europe Neuroblastoma Treatment Drugs Sales 2018-2023 (K Units)
Figure 36. Europe Neuroblastoma Treatment Drugs Revenue 2018-2023 ($ Millions)
Figure 37. Middle East & Africa Neuroblastoma Treatment Drugs Sales 2018-2023 (K Units)
Figure 38. Middle East & Africa Neuroblastoma Treatment Drugs Revenue 2018-2023 ($ Millions)
Figure 39. Americas Neuroblastoma Treatment Drugs Sales Market Share by Country in 2022
Figure 40. Americas Neuroblastoma Treatment Drugs Revenue Market Share by Country in 2022
Figure 41. Americas Neuroblastoma Treatment Drugs Sales Market Share by Type (2018-2023)
Figure 42. Americas Neuroblastoma Treatment Drugs Sales Market Share by Application (2018-2023)
Figure 43. United States Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. Canada Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 45. Mexico Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 46. Brazil Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 47. APAC Neuroblastoma Treatment Drugs Sales Market Share by Region in 2022
Figure 48. APAC Neuroblastoma Treatment Drugs Revenue Market Share by Regions in 2022
Figure 49. APAC Neuroblastoma Treatment Drugs Sales Market Share by Type (2018-2023)
Figure 50. APAC Neuroblastoma Treatment Drugs Sales Market Share by Application (2018-2023)
Figure 51. China Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. Japan Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. South Korea Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. Southeast Asia Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. India Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. Australia Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 57. China Taiwan Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 58. Europe Neuroblastoma Treatment Drugs Sales Market Share by Country in 2022
Figure 59. Europe Neuroblastoma Treatment Drugs Revenue Market Share by Country in 2022
Figure 60. Europe Neuroblastoma Treatment Drugs Sales Market Share by Type (2018-2023)
Figure 61. Europe Neuroblastoma Treatment Drugs Sales Market Share by Application (2018-2023)
Figure 62. Germany Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. France Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. UK Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 65. Italy Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 66. Russia Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 67. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Country in 2022
Figure 68. Middle East & Africa Neuroblastoma Treatment Drugs Revenue Market Share by Country in 2022
Figure 69. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Type (2018-2023)
Figure 70. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Application (2018-2023)
Figure 71. Egypt Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. South Africa Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. Israel Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 74. Turkey Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 75. GCC Country Neuroblastoma Treatment Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 76. Manufacturing Cost Structure Analysis of Neuroblastoma Treatment Drugs in 2022
Figure 77. Manufacturing Process Analysis of Neuroblastoma Treatment Drugs
Figure 78. Industry Chain Structure of Neuroblastoma Treatment Drugs
Figure 79. Channels of Distribution
Figure 80. Global Neuroblastoma Treatment Drugs Sales Market Forecast by Region (2024-2029)
Figure 81. Global Neuroblastoma Treatment Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 82. Global Neuroblastoma Treatment Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 83. Global Neuroblastoma Treatment Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 84. Global Neuroblastoma Treatment Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 85. Global Neuroblastoma Treatment Drugs Revenue Market Share Forecast by Application (2024-2029)
